CALGARY, Canada, September 2 /PRNewswire/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours. The Principal Investigator is Dr. Miguel Villalona-Calero, Professor Division of Hematology/Oncology and Department of Internal Medicine and Pharmacology at The Ohio State University Comprehensive Cancer Center.

PARIS, September 2 /PRNewswire/ -- Alcatel-Lucent's Board of Directors (Euronext Paris and NYSE: ALU) yesterday approved the appointment of Philippe Camus as the company's non-executive Chairman as of October 1st, 2008. Ben Verwaayen is appointed as the company's chief executive officer. Ben will also join the company's Board of Directors.

WASHINGTON, September 1 /PRNewswire/ --

- One-Year Data Find Angioplasty and Stenting Safe and Effective in Patients for Whom Standard Therapy Has Been Open-Heart Surgery

Data announced today from the landmark SYNTAX trial indicate that patients with very complex coronary artery disease can safely choose to be treated with angioplasty and drug-eluting stents rather than open-heart surgery, says The Society for Cardiovascular Angiography and Interventions (SCAI). The one-year results of SYNTAX also show that most patients with left main and multi-vessel disease who undergo angioplasty and stenting will not need a second revascularization procedure in the first year.

GREENWICH, England, September 1 /PRNewswire/ --

WASHINGTON, September 1 /PRNewswire/ --

- At One Year, Angioplasty and Stenting Matches Bypass Surgery for Safety and Effectiveness in Patients with Complex Medical Condition

Patients with both diabetes and advanced blockages in at least three heart vessels will find good news in new findings announced today from the CARDia trial, says The Society for Cardiovascular Angiography and Interventions (SCAI). The one-year findings of the new study indicate that these patients can safely choose to undergo angioplasty and stenting rather than open-heart surgery.

BERLIN, September 1 /PRNewswire/ --

- Henning Ogberg Appointed New Vice President Sales - eleven Opens New Office in Munich

eleven, Germany's leading integrated e-mail security solutions provider, is expanding its sales activities in Germany and Europe and planning to enter markets in other regions. eleven has engaged Henning Ogberg as its new Vice President Sales to head up the newly opened eleven office in Munich and coordinate the market expansion starting September 1, 2008. The market expansion's purpose is to cement eleven's market leader status in Germany and build a strong presence in other markets in Europe and around the world.